Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/19
A61K-009/10
출원번호
US-0557486
(2006-11-07)
등록번호
US-8728525
(2014-05-20)
발명자
/ 주소
Brown, Larry R.
Yang, Mark X.
O'Connell, Ed
출원인 / 주소
Baxter International Inc.
대리인 / 주소
Marshall, Gerstein & Borun LLP
인용정보
피인용 횟수 :
0인용 특허 :
100
초록▼
The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhanc
The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical particles that are substantially amorphous or non-crystalline and are injectable through fine bore needles at high concentrations. The particles exhibit the pharmacokinetic and pharmacodynamnic properties of the active agent. The disclosure has special application for higher molecular weight proteins such as antibodies.
대표청구항▼
1. An injectable pharmaceutical composition of microparticles comprising substantially amorphous protein microparticles, the composition providing a concentration of at least about 50 mg of said protein in said microparticles per ml of said composition, and wherein a solution of the protein has an i
1. An injectable pharmaceutical composition of microparticles comprising substantially amorphous protein microparticles, the composition providing a concentration of at least about 50 mg of said protein in said microparticles per ml of said composition, and wherein a solution of the protein has an identifiable value of a selected pharmacokinetic property when measured in a medium and when administered by a given route, and said composition of microparticles exhibits substantially the same identifiable value of said selected pharmacokinetic property in said medium and when administered by said given route, said pharmacokinetic property selected from the group consisting of Cmax, Tmax, area under the curve (AUC), and relative bioavailability. 2. The composition of claim 1 wherein said protein has a molecular weight of at least about 25,000 Daltons. 3. The composition of claim 1 wherein said protein is an antibody. 4. The composition of claim 1, wherein said protein comprises an antibody selected from the group consisting of monoclonal antibodies, polyclonal antibodies, IVIG, antibody fragments, trap molecules, single chain antibodies, recombinant forms thereof and combinations thereof. 5. The composition of claim 1 wherein said protein is a monoclonal antibody. 6. The composition of claim 1 wherein said protein is insulin. 7. The composition of claim 2 wherein said protein is soluble from at least about 0.5 mg/ml under physiological conditions. 8. The composition of claim 1 wherein said composition provides a concentration of said protein of up to about 500 mg per ml. 9. The composition of claim 1 wherein said composition provides a concentration of said protein from about 100 mg per ml to about 500 mg per ml. 10. The composition of claim 1 wherein said composition provides a concentration of said protein from about 150 mg per ml to about 500 mg per ml. 11. The composition of claim 1 wherein said composition is a subcutaneously injectable composition. 12. The composition of claim 11, wherein a clinically effective amount of said protein microparticles is dispersed in not greater than about 10 mls of said composition. 13. The composition of claim 11, wherein a clinically effective amount of said protein microparticles is dispersed in not greater than about 2 mls of said composition. 14. The composition of claim 11 wherein a clinically effective amount of said composition is injectable in less than about two minutes with a clinically acceptable amount of force. 15. The composition of claim 1, wherein said protein microparticles have an average particle size of not greater than about 50 microns, and the injectable composition passes through an injection needle of 20 gauge or finer. 16. The composition of claim 1 wherein one ml of said composition containing up to about 400 mg/ml of said protein is capable of being injected in about 45 seconds or less with a clinically acceptable amount of force. 17. The composition of claim 1, wherein said microparticles further include an excipient. 18. A microparticle comprising a substantially amorphous antibody wherein a solution of the antibody has an identifiable value of a selected pharmacokinetic property when measured in a medium and when administered by a given route, and said microparticle exhibits substantially the same identifiable value of said selected pharmacokinetic property when measured in the same medium and when administered by said given route, said pharmacokinetic property selected from the group consisting of Cmax, Tmax, area under the curve (AUC), and relative bioavailability. 19. The microparticle of claim 18, therein said antibody is a monoclonal antibody. 20. The microparticle of claim 18, wherein said microparticle is a microsphere having a particle size not greater than about 50 microns. 21. The microparticle of claim 18, wherein said microparticle comprises an antibody selected from the group consisting of a monoclonal antibody, a polyclonal antibody, IVIG, a monoclonal antibody fragment, a trap molecule, a single chain antibody, a recombinant form thereof, and combinations thereof. 22. The microparticle of claim 18, wherein said microparticle further includes an excipient. 23. The microparticle of claim 18, wherein said antibody comprises from about 20 to about 100 weight percent of said microparticle, based on the total weight of the microparticle. 24. A method for administering a protein microparticle composition for an application that requires a selected pharmacokinetic property wherein said pharmacokinetic property is measured in a given medium and administered by a given route, comprising: providing protein molecules that have an identifiable value of a selected pharmacokinetic property within a medium and in soluble form; forming said protein molecules into microparticles; formulating said microparticles for administering the microparticles as said composition; and administering said composition to an individual, whereby said microparticle composition has a value of said selected pharmacokinetic property that is substantially the same as said identifiable value when measured in said medium and when administered by said given route. 25. The method of claim 24 wherein said protein molecules are of a therapeutic agent. 26. The method of claim 24 wherein said protein molecules are of an antibody. 27. The method of claim 24 wherein said protein molecules are of insulin. 28. The method of claim 24 wherein said protein molecules are soluble in the medium from at least about 0.51 mg/ml to about 500 mg/ml. 29. The method of claim 24 wherein said selected pharmacokinetic property is selected from the group consisting of one or more of Cmax, Tmax, area under the curve (AUC), and relative bioavailability. 30. The method of claim 24 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 50 mg/ml. 31. The method of claim 24 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 200 mg/ml. 32. The method of claim 24 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 400 mg/ml. 33. The method of claim 24 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 500 mg/ml. 34. The method of claim 24 wherein said administering is through a needle of 20 gauge or finer. 35. A method of mimicking a pharmacokinetic property of a native form of a protein, comprising: providing native protein molecules that have a selected pharmacokinetic property when administered in native form; forming microparticles from said protein molecules to provide a non-native form of protein molecules; and administering said non-native form of protein microparticles in a manner that mimics said selected pharmacokinetic property. 36. The method of claim 35 wherein said forming provides said protein molecules as a composition and at a concentration of at least about 50 mg/ml. 37. The method of claim 35 wherein said forming provides said protein molecules as a composition and at a concentration of at least about 200 mg/ml. 38. The method of claim 35 wherein said forming provides said protein molecules as a composition and at a concentration of at least about 400 mg/ml. 39. The method of claim 35 wherein said forming provides said protein molecules as a composition and at a concentration of at least about 500 mg/ml. 40. An injectable pharmaceutical composition of microparticles comprising a suspension of substantially amorphous protein microparticles, the composition providing a concentration of at least about 50 mg of said protein in said microparticles per ml of said composition, said protein having a molecular weight of at least about 25,000 Daltons, and wherein an effective amount of said composition is capable of being injected in less than about two minutes with a clinically acceptable amount of force. 41. The composition of claim 40 wherein said effective amount is contained in a dose of about 2 mls or less. 42. The composition of claim 40 wherein said composition provides said protein molecules at a concentration of at least about 300 mg/ml. 43. The composition of claim 40 wherein said composition provides said protein molecules at a concentration of at least about 400 mg/ml. 44. The composition of claim 40 wherein said composition provides said protein molecules at a concentration of at least about 500 mg/ml. 45. The composition of claim 40 wherein one ml of said formulation containing up to about 400 mg/ml of said protein is capable of being injected in from less than about 45 seconds with a clinically acceptable amount of force. 46. A method for administering protein molecules in microparticle form for an application, comprising: providing protein molecules having a molecular weight of at least about 25,000 Daltons; forming said protein molecules into microparticles; formulating said microparticles for administering said microparticles as a composition; and administering said formulation to an individual, wherein said microparticles are capable of being injected in less than about two minutes with a clinically acceptable amount of force. 47. The method of claim 46 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 50 mg/ml. 48. The method of claim 46 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 200 mg/ml. 49. The method of claim 46 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 400 mg/ml. 50. The method of claim 46 wherein said formulating provides said protein molecules in said composition at a concentration of at least about 500 mg/ml. 51. The composition of claim 40 wherein said protein is insulin. 52. The method of claim 24 wherein said administering injects said composition in less than about two minutes with a clinically acceptable amount of force. 53. The method of claim 24 wherein said administering injects at least one ml of the composition in about 45 seconds or less with a clinically acceptable amount of force. 54. The method of claim 24 where said formulating prepares the composition for subcutaneous delivery, and said administrating is carried out subcutaneously. 55. The method of claim 24 wherein said administering is of a non-soluble microparticle form of said protein molecules, and said protein molecules are not endocytosed by cells of the immune system of the individual.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (100)
Ramstack, J. Michael, Apparatus for preparing microparticles using liquid-liquid extraction.
Hubbell Jeffrey A.,CHX ; Kieras Mark T. ; Ron Eyal S. ; Rowe Stephen C., Biodegradable macromers for the controlled release of biologically active substances.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Singh Maninder (Mountain Brook Rodeo CA) Nunberg Jack H. (Mountain Brook Oakland CA) Tice Thomas R. (Mountain Brook Birmingham AL) Hudson Michael E. (Mountain Brook Gardendale AL) Gilley Richard M. (, Controlled-release formulations of interleukin-2.
Frank Caruso DE; Rachel Anne Caruso DE; Edwin Donath DE; Helmuth Mohwald DE; Gleb Sukhorukov RU, Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Cohen Smadar (Petach-Tickva ILX) Bano Carmen (Valencia PA ESX) Visscher Karyn B. (State College PA) Chow Marie (Brookline MA) Allcock Harry R. (State College PA) Langer Robert S. (Newton MA), Ionically cross-linked polymeric microcapsules.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Tice Thomas R. (Birmingham AL) Dillon Deborah L. (Helena AL) Mason David W. (Birmingham AL) McRae-McFarlane Amanda (Vastra Frolunda SEX) Dahlstrom Annica B. (Askin SEX), Method for stimulating nerve fiber growth.
Onda Mitsuhiko,JPX ; Lvov Yuri,JPX ; Ariga Katsuhiko,JPX ; Kunitake Toyoki,JPX, Method for the preparation of an immobilized protein ultrathin film reactor and a method for a chemical reaction by using an immobilized protein ultrathin film reactor.
Jones David Hugh,GBX ; Farrar Graham Henry,GBX ; Clegg James Christopher Stephen,GBX, Method of making microencapsulated DNA for vaccination and gene therapy.
Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Eldridge John H. (Birmingham AL) Staas Jay K. (Birmingham AL) Hollingshead Melinda G. (Birmingham AL) Shannon William M. (Birmingham A, Method of potentiating an immune response.
Bot, Adrian I.; Tarara, Thomas E.; Weers, Jeffry G.; Kabalnov, Alexev; Schutt, Ernest G.; Dellamary, Luis A., Particulate delivery systems and methods of use.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Ramstack J. Michael (Lebanon OH) Herbert Paul F. (Wayland MA) Strobel Jan (Westchester OH) Atkins Thomas J. (Cincinnati OH), Preparation of biodegradable microparticles containing a biologically active agent.
Cha Younsik (Salt Lake City UT) Choi Young Kweon (Salt Lake City UT) Pai Chaul Min (Taejon KRX), Preparation of peptide containing biodegradable microspheres by melt process.
Williams, III, Robert O.; Johnston, Keith P.; Young, Timothy J.; Rogers, True L.; Barron, Melisa K.; Yu, Zhongshui; Hu, Jiahui, Process for production of nanoparticles and microparticles by spray freezing into liquid.
Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
Margolin, Alexey L.; Khalaf, Nazar K.; St. Clair, Nancy L.; Rakestraw, Scott L.; Shenoy, Bhami C., Stabilized protein crystals formulations containing them and methods of making them.
Park, Jin Kyu; Park, Mork Soon; Kim, Dong Seon; Lim, Il Ho; Jee, Ung Kil; Myung, Pyung Keun; Kim, San Beom; Jung, Goo Young, Sustained release microparticle and method for preparing the same.
Reid Robert H. (Kensington MD) Boedeker Edgar C. (Chevy Chase MD) van Hamont John E. (Shape MD BEX) Setterstrom Jean A. (Takoma Park MD), Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompa.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.